Cytokinetics (CYTK) Net Income towards Common Stockholders (2010 - 2026)

Cytokinetics (CYTK) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$185.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 12.06% year-over-year to -$185.2 million; the TTM figure through Mar 2026 stood at -$672.6 million (down 10.91% YoY), while the FY2025 annual figure was -$917.7 million, up 26.54% from the prior year.
• Net Income towards Common Stockholders fell to -$185.2 million in Q1 2026 per CYTK's latest filing, from -$176.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$13.7 million in Q2 2022 and bottomed at -$188.9 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$133.9 million across 5 years, with a median of -$136.4 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders jumped 86.38% — and 2023, when it sank 843.6%.
• Cytokinetics' Net Income towards Common Stockholders stood at -$140.9 million in 2022, then advanced by 17.26% to -$116.6 million in 2023, then dropped by 27.44% to -$148.6 million in 2024, then slipped by 18.45% to -$176.0 million in 2025, then fell by 5.25% to -$185.2 million in 2026.
• Business Quant data shows CYTK's Net Income towards Common Stockholders at -$185.2 million in Q1 2026, -$176.0 million in Q4 2025, and -$188.9 million in Q3 2025.